Titlebook: Handbook of Antimicrobial Resistance; Matthias Gotte (Editor-in-chief),Albert Berghuis,D Reference work 2017 Springer Science+Business Med

廣大

Drug-Resistant Tuberculosisrbidity and mortality in many parts of the world. In 2012, 8.6 million people became sick with tuberculosis, and 1.3 million died from this curable disease (World Health Organization 2013a). While the majority of cases are caused by strains susceptible to all antituberculosis antibiotics, drug resis

格子架

The Biochemistry of Quinoline Antimalarial Drug Resistanceresistance. However, additional facets to resistance biochemistry are emerging, and it is now clear that multiple quinoline drug resistance phenotypes exist in different regions of the globe. Different public health policies and drug use histories across the globe, along with natural genetic drift,

GRACE

Drug Resistance in ,o vaccine available yet, the control of these parasites relies solely on chemotherapy. Low-cost antimony-derived compounds remain the primary antileishmanial treatment in most developing countries. Increasing drug resistance towards these molecules has forced the use of alternative therapies in high

Dysarthria

ROOF

Fibrin

Seif Emseih,Ghassan Soleiman Abu-Sittahe risk of liver disease progression, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Nucleos(t)ide analogue monotherapy is commonly used as first-line therapy, and most patients will require long-term antiviral therapy. As for all direct-acting antiviral agents, the emergence of

strdulate

蚊子

https://doi.org/10.1007/978-981-97-2504-5tagens of retroviral genomes. In humans, the APOBEC3 family comprises seven different proteins (APOBEC3A [A3A] to A3H), whose cytidine deaminase activity – if left unchecked – results in extensive mutagenesis of the HIV-1 genome. There is emerging evidence that cytidine deaminases other than A3G pla

MERIT

Assessing the magnitude of the problemt accomplished by combining several drugs with potent antiviral activity across multiple genotypes, with each possessing a high barrier to resistance, different mechanisms of action, and no cross-resistance. A novel class of anti-HCV agents that have shown great promise in HCV patients – the cycloph

adequate-intake